Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.

Row rect Shape Decorative svg added to bottom
Back to Webinars
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies

Featured Speakers: David Miklos, MD, PhD, Chief Clinical Director, Blood and Marrow Transplantation and Cellular Therapy, Cancer Cell Therapy Stanford University

What's Inside

In this Webinar we discuss:

CAR-T benefits are T cell dependent

Treatment schema for CAR-T cell therapy

Explore several case studies

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Row rect Shape Decorative svg added to top
Watch the Webinar
Back to the Top